Clinical characteristics and prognosis of primary pancreatic carcinoid tumors: A report of 13 cases from a single institution
- Authors:
- Feng‑Hua Liu
- Chong Wang
- Ya‑Ling Xing
- Jiang‑Hua Wu
- Yong Tang
View Affiliations
Affiliations: Department of Gynecological Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, P.R. China, Department of General Surgery, Tianjin First Central Hospital, Tianjin 300190, P.R. China, Department of Pancreatic Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, P.R. China, Department of Pathology, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, P.R. China
- Published online on: December 8, 2014 https://doi.org/10.3892/ol.2014.2776
-
Pages:
780-784
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Abstract
The present study aimed to analyze the diagnosis and treatment of 13 cases of pancreatic carcinoid tumors during a 56‑year period at the Tianjin Medical University Cancer Institute and Hospital (Tianjin, China). The data from 13 cases, consisting of 5 males and 8 females (mean age, 50 years), were collected and analyzed. Hematoxylin‑eosin and immunohistochemistry staining were performed to investigate the expression of neuron‑specific enolase (NSE), cytokeratin (CK), chromogranin A (CgA) and synaptophysin (Syn) in the tumors. The affected patients suffered abdominal and/or back pain without typical carcinoid syndrome. Radical resection was performed in 10 cases and regional resection in one case. The remaining two patients exhbited remote metastasis, and so were treated with single and double bypass surgery (choledochojejunostomy and gastrojejunostomy/choledochojejunostomy, respectively). The expression of CK, Syn, CgA and NSE was positive in nine (69.23%), 10 (76.92%), five (38.46%) and eight (61.54%) cases, respectively. The median survival time was 26.6 months. In conclusion, in patients with pancreatic carcinoid tumors that exhibit no typical carcinoid syndrome, such as those in the present study, the diagnosis can be confirmed by pathological examination and surgery is the most effective treatment.
View References
|
1
|
Modlin IM, Shapiro MD and Kidd M: An
analysis of rare carcinoid tumors: clarifying these clinical
conundrums. World J Surg. 29:92–101. 2005. View Article : Google Scholar
|
|
2
|
No authors listed. Plastic insulin
syringes. Br Med J (Clin Res Ed). 296:11951988. View Article : Google Scholar
|
|
3
|
Tamm EP, Kim EE and Ng CS: Imaging of
neuroendocrine tumors. Hematol Oncol Clin North Am. 21:409–432.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Soga J: Carcinoids and their variant
endocrinomas. An analysis of 11842 reported cases. J Exp Clin
Cancer Res. 22:517–530. 2003.
|
|
5
|
Hassan MM, Phan A, Li D, Dagohoy CG, Leary
C and Yao JC: Risk factors associated with neuroendocrine tumors: A
U.S.-based case-control study. Int J Cancer. 123:867–873. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Capurso G, Falconi M, Panzuto F,
Rinzivillo M, Boninsegna L, Bettini R, Corleto V, Borgia P,
Pederzoli P, Scarpa A and Delle Fave G: Risk factors for sporadic
pancreatic endocrine tumors: a case-control study of prospectively
evaluated patients. Am J Gastroenterol. 104:3034–3041. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chu P, Wu E and Weiss LM: Cytokeratin 7
and cytokeratin 20 expression in epithelial neoplasms: a survey of
435 cases. Mod Pathol. 13:962–972. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Varas-Lorenzo MJ: Long-standing malignant
pancreatic carcinoid treated with octreotide. Rev Esp Enferm Dig.
102:662–666. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Torske KR and Thompson LD: Adenoma versus
carcinoid tumor of the middle ear: a study of 48 cases and review
of the literature. Mod Pathol. 15:543–555. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cernaianu G, Tannapfel A, Nounla J,
Gonzalez-Vasquez R, Wiesel T and Tröbs RB: Appendiceal carcinoid
tumor with lymph node metastasis in a child: case report and review
of the literature. J Pediatr Surg. 45:e1–e5. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
He XW, Wu XJ, He XS, Zou YF, Ke J, Wang JP
and Lan P: Clinicopathologic analysis of eight cases of pancreatic
carcinoid tumors. Chin Med J (Engl). 122:1591–1594. 2009.
|
|
12
|
Zuetenhorst JM and Taal BG: Metastatic
carcinoid tumors: a clinical review. Oncologist. 10:123–131. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kaltsas GA, Besser GM and Grossman AB: The
diagnosis and medical management of advanced neuroendocrine tumors.
Endocr Rev. 25:458–511. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chowsanitphon J: Carcinoid tumor. Oncol
Nurs Forum. 37:677–679. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bajetta E, Ferrari L, Martinetti A, Celio
L, Procopio G, Artale S, Zilembo N, Di Bartolomeo M, Seregni E and
Bombardieri E: Chromogranin A, neuron specific enolase,
carcinoembryonic antigen, and hydroxyindole acetic acid evaluation
in patients with neuroendocrine tumors. Cancer. 86:858–865. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pavel M, Kidd M and Modlin I: Systemic
therapeutic options for carcinoid. Semin Oncol. 40:84–99. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zarina AL, Hamidah A, Zulkifli SZ,
Zulfiqar MA and Jamal R: Malignant pancreatic carcinoid tumour.
Singapore Med J. 48:e320–e322. 2007.PubMed/NCBI
|
